Additional file 3: Tables S2. of Performance of the marginal structural cox model for estimating individual and joined effects of treatments given in combination

Multivariate parameter estimates for covariate association with the risk of anal cancer in HIV-infected persons: comparison of weighted Cox MSM and standard time dependent Cox models. (DOCX 22 kb

Univariable and multivariable analyzes for loss of LTNP and HIV controller status.

<p>Univariable and multivariable analyzes for loss of LTNP and HIV controller status.</p

Characteristics of LTNP and HIC patients identified in 2005 who maintained or lost their status during follow-up.

<p>Characteristics of LTNP and HIC patients identified in 2005 who maintained or lost their status during follow-up.</p

Loss of long-term non-progressor and HIV controller status over time in the French Hospital Database on HIV - ANRS CO4 - Fig 1

<p><b>Cumulative incidence of loss of LTNP (panel A) and HIV controller (panel B) status, treatment initiation and non AIDS deaths since 2005. A:</b> Long-term non-progressors (n = 171). <b>B:</b> HIV controllers (n = 72).</p

Durability, immunovirological response and clinical outcomes of maraviroc-based regimens up to month 30 according to viral tropism.

<p>^a Adjusted on type of treatment change, gender, age, Sub-Saharan origin, HCV co-infection, AIDS status, CD4 nadir, CD4, plasma HIV-1 RNA, OI prophylaxis, number of past ARV drugs, duration of prior ARV exposure, NRTI, boosted PI, raltegravir, etravirine at baseline. ^b 53 unknown viral tropism because unavailable data; 30 because viral tropism was not tested; 6 because the result of test was indeterminate.</p

Discontinuations.

<p>Discontinuations.</p

Kaplan-Meier plots showing, according to R5 or non-R5 viral tropism, the times (a) to maraviroc discontinuation, (b) to a virological response VL<50 copies/ml, (c) to a sustained gain of at least 100 CD4 cells/mm³, (d) to hospitalization for a non AIDS event, an AIDS event or death.

<p>Kaplan-Meier plots showing, according to R5 or non-R5 viral tropism, the times (a) to maraviroc discontinuation, (b) to a virological response VL<50 copies/ml, (c) to a sustained gain of at least 100 CD4 cells/mm³, (d) to hospitalization for a non AIDS event, an AIDS event or death.</p

Individual selection.

<p>Individual selection.</p

Patients with a first episode of PCP in 2004–2011: characteristics at PCP diagnosis.

<p>Figures are medians (Interquartile Range) or N (%); °P value: χ2 test for categorical variables and Kruskal-Wallis test for continuous variables, comparison between PE non-prior ADI, PE prior ADI, and reference groups.</p><p>* Percentage of patients with CD4 cell count >350/mm³ after cART initiation;</p><p>**percentage of patients with HIV viral load<500 copies/ml after cART initiation ADI: AIDS-defining illness, MSM: Men who have Sex with Men, IDU: Intravenous Drug User.</p

Patient selection flow diagram.

<p>Patient selection flow diagram.</p